Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
四川科倫博泰生物醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6990)

INSIDE INFORMATION
(1) PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY
(2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "**Company**") pursuant to Rule 13.09(2)(a) and Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION

Reference is made to the Guidelines on Application for "Full Circulation" of Domestic Unlisted Shares of H-share Companies (《H股公司境內未上市股份申請"全流通"業務指引》) issued by the China Securities Regulatory Commission (the "**CSRC**") on November 14, 2019 and further amended on August 10, 2023 (the "**Guidelines**").

In view of the Guidelines, the board (the "**Board**") of directors (the "**Directors**") of the Company has considered and approved the proposed implementation of full circulation (the "**H Share Full Circulation**") of up to 3,572,088 domestic shares and 4,642,190 unlisted foreign shares of the Company held by certain shareholders of the Company (the "**Shareholders**"). On the same day, the Company submitted the filing application to the CSRC in respect of the H Share Full Circulation.

As at the date of this announcement, the H Share Full Circulation is subject to the obtaining of all relevant approvals, including the filing notice of the CSRC, and the conversion of such shares into H shares of the Company ("**H Shares**") and the Listing Committee of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") granting listing of, and permission to deal in, the H Shares on the Main Board of the Stock Exchange (the "**Conversion and Listing**"). The final number of shares to which the H Share Full Circulation applies will be subject to the obtaining of all such relevant approvals.

The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in accordance with the Inside Information Provisions and/or the requirements of the Listing Rules.

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The Board has considered and approved the resolution on certain proposed amendments (the "**Proposed Amendments**") to the articles of association of the Company (the "**Articles of Association**") to reflect the change in share capital structure of the Company which will result from the completion of the full circulation of certain domestic shares and unlisted foreign shares of the Company held by certain Shareholders. The Proposed Amendments will take effect upon completion of the H Share Full Circulation. Pursuant to Article 18 of the existing Articles of Association, no further Shareholders' approval is required for the Proposed Amendments.

The H Share Full Circulation and the Conversion and Listing are subject to relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, September 19, 2025

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.